Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 179 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: fluoxetine Clear all
Completed Phase 2 Interventional Results available

Pharmacological Intervention Project (Fluoxetine)

NCT00027378
View directory record Official record
Conditions
Alcoholism, Depression
Interventions
fluoxetine (Prozac), Placebo plus Treatment As Usual
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
15 Years to 20 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 18, 2026, 1:11 AM EDT
Terminated Phase 4 Interventional Results available

Fluoxetine vs Aripiprazole Comparative Trial (FACT)

NCT02357849
View directory record Official record
Conditions
Attenuated Psychosis Syndrome
Interventions
Aripiprazole, Fluoxetine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
12 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy for Depression Relapse Prevention in Children and Adolescents

NCT00158301
View directory record Official record
Conditions
Depression
Interventions
Cognitive behavioral therapy (CBT), Drug therapy
Behavioral · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
11 Years to 18 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

NCT00666757
View directory record Official record
Conditions
Depression
Interventions
duloxetine, fluoxetine, citalopram, paroxetine, sertraline
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
61
States / cities
Carson, California • Irvine, California • San Diego, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2010 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Phase 2 Interventional Results available

An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression

NCT03222570
View directory record Official record
Conditions
Depressive Disorder
Interventions
Interpersonal Psychotherapy for Depressed Adolescents, Selective Serotonin Reuptake Inhibitor, Usual Care
Behavioral · Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Not applicable Interventional Results available

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

NCT02655354
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation, Substance-Related Disorders, Mild Cognitive Impairment, Quality of Life, Pain, Wounds and Injury, Brain Injuries, Chronic Disease
Interventions
Motivational Interviewing, Cognitive Behavioral Therapy Elements, Care Management, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Citalopram, Venlafaxine, Duloxetine, Mirtazapine, Diphenhydramine, Trazodone, Prazosin
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
24
States / cities
Scottsdale, Arizona • Beverly Hills, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 18, 2026, 1:11 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study

NCT01944657
View directory record Official record
Conditions
1. Major Depressive Disorder
Interventions
Supplemental TMS, Standard Medication Monotherapy
Device · Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 18, 2026, 1:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding Sleep Problems in Children With Autism Spectrum Disorder

NCT00691080
View directory record Official record
Conditions
Sleep Problems
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
4 Years to 9 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
3
States / cities
New York, New York • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 18, 2026, 1:11 AM EDT
Terminated Not applicable Interventional Results available

Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression

NCT01740726
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Behavioral Activation, Fluoxetine
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 18, 2026, 1:11 AM EDT
Terminated Phase 1 Interventional Results available

Piloting Acute Care to Primary Care Linkage of Safety Net Patients

NCT01347541
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Cognitive Behavioral Therapy, Motivational Interviewing, FDA-Approved Anti-Anxiety Medications, Standard Care Control
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

NCT01254305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dichotic Listening as a Predictor of Medication Response in Depression

NCT00296725
View directory record Official record
Conditions
Major Depression, Dysthymia, Depressive Disorder Not Otherwise Specified
Interventions
Fluoxetine, Imipramine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Not applicable Interventional Results available

Perioperative Mental Health in Orthopedic Surgery

NCT05697835
View directory record Official record
Conditions
Orthopedic Surgery, Older Adults, Depression, Anxiety
Interventions
Behavioral activation, Medication optimzation, Care as usual
Behavioral · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 18, 2026, 1:11 AM EDT
Recruiting Early Phase 1 Interventional

The Effects of Fluoxetine and/or DHEA

NCT03228732
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Placebo Oral Tablet, Fluoxetine, DHEA, Fluoxetine and DHEA
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

NCT00005850
View directory record Official record
Conditions
Anxiety Disorder, Depression, Fatigue, Lung Cancer
Interventions
cisplatin, fluoxetine, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
42
States / cities
Anniston, Alabama • San Diego, California • Washington D.C., District of Columbia + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?

NCT00208897
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Fluoxetine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

NCT01838876
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
88
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Phase 2 Interventional Results available

Effects rTMS Combined With Fluoxetine on Motor Recovery in Stroke Patients

NCT02208466
View directory record Official record
Conditions
Stroke, Motor Function
Interventions
Active Repetitive Transcranial Magnetic Stimulation (rTMS), Fluoxetine, Sham repetitive transcranial magnetic stimulation (rTMS), Placebo Fluoxetine
Device · Drug
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stepped Care for Depression and Musculoskeletal Pain

NCT00118430
View directory record Official record
Conditions
Pain, Depression
Interventions
Stepped Care, Antidepressants, Usual Care
Behavioral · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)

NCT02372799
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Placebo, Fluoxetine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
58
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Phase 3 Interventional

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

NCT00035321
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Olanzapine, Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
30
States / cities
Oceanside, California • San Marcos, California • Torrance, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2006 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Treatment of Childhood Social Phobia

NCT00043537
View directory record Official record
Conditions
Social Phobia
Interventions
Social Effectiveness Therapy for Children (SET-C), Fluoxetine, Pill Placebo
Behavioral · Drug
Lead sponsor
University of Central Florida
Other
Eligibility
8 Years to 16 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2006
U.S. locations
1
States / cities
University of Maryland, College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 18, 2026, 1:11 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

NCT01469377
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Garden Grove, California • National City, California • Oceanside, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 18, 2026, 1:11 AM EDT